Almirall Throws Down Gauntlet To Dupixent With New Lebrikizumab Data
Positive Results Ahead Of Imminent Filing
The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.
You may also be interested in...
The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent.
The French major has secured a fourth approval, in eosinophilic esophagitis, for Dupixent, while the EMA is set to make Sanofi's enzyme replacement therapy, Xenpozyme, the first drug approved in Europe for acid sphingomyelinase deficiency.
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.